TP53 and neoplasm: With regards to tumour suppressors, TP53 was mutated in half of all cases (n = 58, 51%), while CDKN2A/B homozygous deletion was the second most common alteration on our panel (n = 11, 10%), in both cases irrespective of histology and primary tumour location.